DOSE OF REALITY: STUDY FURTHER HIGHLIGHTS THE COST OF BIG PHARMA’S BLOCKBUSTER BAILOUT
Nov 20, 2025
Analysis Finds Excluding Brand Name Drugs Approved to Treat Rare Diseases from… Read More
© 2026 CSRXP- All Rights Reserved
Blog Posts
DOSE OF REALITY: JAMA NETWORK ANALYSIS SHINES LIGHT ON HOW BIG PHARMA PUSHES SALES OF HIGH-PRICED BLOCKBUSTERS BY TARGETING CONSUMERS ON SOCIAL MEDIA
Nov 19, 2025
Brand Name Drug Companies Sidestep Guardrails Meant to Protect American… Read More
BIG PHARMA EARNINGS WATCH: ASTRAZENECA
Nov 11, 2025
Major Drug Company Surpasses Wall Street Forecasts as Price Hikes Fuel Growth… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE, AMGEN & PFIZER
Nov 6, 2025
Major Drug Companies Surpass Wall Street Forecasts as Price Hikes Boost… Read More
THEY SAID IT!: ADMINISTRATION HIGHLIGHTS HOW BIG PHARMA GAMES THE SYSTEM TO UNDERMINE BIOSIMILAR COMPETITION, KEEP PRESCRIPTION DRUG PRICES HIGH
Nov 6, 2025
HHS, FDA and CMS Leaders Emphasize How Streamlining Biosimilar Approvals Will… Read More
BIG PHARMA EARNINGS WATCH: GSK, MERCK, BRISTOL MYERS SQUIBB, ELI LILLY & GILEAD
Nov 3, 2025
Big Pharma Companies Beat Expectations After Hiking Prices on American… Read More
DOSE OF REALITY: NEW ICER REPORT FINDS BIG PHARMA CONTINUES SETTING INCREASINGLY OUT-OF-CONTROL LAUNCH PRICES UNJUSTIFIED BY CLINICAL VALUE
Oct 27, 2025
Launch Prices for 23 New Treatments Exceeding Estimates for a Fair Price Cost… Read More
DOSE OF REALITY: MERCK SURPASSES MILESTONE IN PRODUCT-HOPPING STRATEGY TO BLOCK COMPETITION, KEEP PRICES HIGH ON BLOCKBUSTER CANCER DRUG KEYTRUDA
Oct 22, 2025
DOSE OF REALITY: MERCK SURPASSES MILESTONE IN PRODUCT-HOPPING STRATEGY TO… Read More
DOSE OF REALITY: CONGRESS MUST REPEAL BIG PHARMA’S BLOCKBUSTER BAILOUT THAT WILL COST SENIORS AND TAXPAYERS BILLIONS OF DOLLARS IN PREVIOUSLY UNDERESTIMATED COSTS
Oct 20, 2025
ORPHAN Cures Act Will Enable Big Pharma to Keep Drug Prices High on Top Money… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Oct 16, 2025
Big Pharma Company Beats Wall Street Expectations Following Price Hikes on… Read More
CSRxP: PERA WOULD FURTHER ENABLE BIG PHARMA’S PATENT ABUSE THAT KEEPS PRESCRIPTION DRUG PRICES HIGH
Oct 7, 2025
Senate Judiciary Lawmakers Should Reject Big Pharma-Backed Proposal and… Read More
SECOND OPINION: BIG PHARMA’S RHETORIC OF DEFLECTION DOESN’T ADDRESS CAUSE OF HIGH PRESCRIPTION DRUG PRICES
Oct 6, 2025
PhRMA Continues to Dodge Responsibility for Egregious Pricing Practices and… Read More